Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype. Study Drugs Include: * Daratumumab * lenalidomide * bortezomib * dexamethasone * carboplatin * paclitaxel * pembrolizumab * cyclophosphamide * doxorubicin
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie szpiczaka mnożeniowego wymagającego leczenia lub zaawansowanego raka piersi (stadium II lub III)
- •Planowane leczenie określoną kombinacją chemioterapii i immunoterapii
- •Potwierdzony genetycznie typ krwi Duffy null
- •Wiek minimum 18 lat
- •Możliwość zrozumienia i podpisania świadomej zgody
✗ Disqualifies
- •Bardzo niski poziom pewnego rodzaju białych krwinek (ANC < 500) w ciągu 7 dni przed rozpoczęciem leczenia
- •Już rozpoczęte leczenie drugiego cyklu chemioterapii
- •Wcześniejsze leczenie immunoterapią (pembrolizumab) lub chemioterapią (doksorubicyna, cyklofosfamid)
- •Uczestnictwo w innym badaniu klinicznym z innymi badanymi leczeniami
- •Inne schorzenia lub leki wpływające na białe krwinki
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Dana-Farber Cancer Institute
Boston, United States
Trial contact
Andrew Hantel, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.